15 December 2017Americas
State law can’t compel ‘patent dance’, rules Federal Circuit
State law cannot force drug makers to participate in the ‘patent dance’ provided for by the Biologics Price Competition and Innovation Act (BPCIA).
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
14 September 2017 The US Department of Justice (DoJ) has voiced its opinion on the biosimilar dispute between Amgen and Sandoz.
Americas
12 June 2017 The US Supreme Court has ruled that biosimilar applicants may provide notice to the manufacturer before obtaining a licence from the Food and Drug Administration for their biosimilars.
Editor's picks
Editor's picks
Americas
14 September 2017 The US Department of Justice (DoJ) has voiced its opinion on the biosimilar dispute between Amgen and Sandoz.
Americas
12 June 2017 The US Supreme Court has ruled that biosimilar applicants may provide notice to the manufacturer before obtaining a licence from the Food and Drug Administration for their biosimilars.
Americas
14 September 2017 The US Department of Justice (DoJ) has voiced its opinion on the biosimilar dispute between Amgen and Sandoz.
Americas
12 June 2017 The US Supreme Court has ruled that biosimilar applicants may provide notice to the manufacturer before obtaining a licence from the Food and Drug Administration for their biosimilars.